Duchenne Muscular Dystrophy Community, News and Tools

Our Clinical Trials Hub makes it easier to find, explore, and compare Duchenne clinical trials. With AI-assisted updates and multilingual access, reliable clinical trial information is always within reach.

10 LANGUAGES

Worldwide Access

AI-POWERED

Always Updated

SMART INSIGHTS

Research Statistics

Together, We Can Make a Difference in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a rare genetic disorder that affects approximately 1 in every 5,000 boys worldwide. Although many people have never heard of Duchenne, thousands of families face its challenges every single day. Behind every diagnosis is a child with dreams, a family with hopes, and a community determined never to give up. We call these families and individuals DMD Warriors because their courage, resilience, and determination inspire us to keep moving forward.

DMDWarrior.com was founded with a clear mission: to raise global awareness of Duchenne muscular dystrophy, accelerate the development of better treatments, and make therapies accessible and affordable for everyone, everywhere. As one of the world’s most visited and actively updated interactive platforms dedicated to Duchenne, we bring together the latest research, clinical trial updates, treatment developments, and advocacy resources. We believe that no family should be left behind because of geography or financial barriers. Together, we stand for progress, equal access, and a brighter future for every DMD Warrior.

Duchenne muscular dystrophy awareness motocross rider performing a jump in autumn

What is our purpose?

Our purpose is to make sure that no child with Duchenne muscular dystrophy is left behind. We believe every child deserves access to the best possible treatments, regardless of their family’s financial situation or country of residence. We advocate for affordable medicines, faster treatment approvals, transparent clinical trial results, and equal access to life-changing therapies. We challenge barriers, question the status quo, and bring together families, researchers, and advocates worldwide. Our mission is simple: to turn scientific progress into real hope, meaningful opportunities, and better lives for everyone living with Duchenne.

pharmacy treatments Home

Ease of Access to Treatments

In many countries, DMD treatments are not available, and families incur huge costs for travel abroad.

money bag Home

Reducing Treatment Costs

Treatments for DMD are very expensive, and it is nearly impossible for families to cover these costs themselves.

social media Home

Raising Awareness

We do not want any child to die. If you also want to find a solution to this situation, follow us on social media.

DMD Reach

DMDWarrior has built a global digital community dedicated exclusively to Duchenne muscular dystrophy (DMD), connecting families with clear, accessible and up-to-date information in 10 languages. Our independent platform reaches families, caregivers and the wider DMD community across the world.

10+
Languages

One Global DMD Community

86%
World Population

Reached In Local Languages

380K+
Unique Visitors

Engaging With DMDWarrior

2.05M+
Total Impressions

Across Our Global Platform

Discover our tools now!

clinical trials icon Home

Find Duchenne clinical trials faster with smart search, filters, and easy-to-use trial information!

exon check tool icon Home

Analyze DMD exon deletions and discover approved and potential treatments for your mutation profile.

dictionary icon Home

The Duchenne Dictionary is a clear, accessible guide demystifying medical terms for the Duchenne community.

android ios app icon Home

Our Android and iOS apps are now in testing and will be released soon with trusted DMD resources soon.

Duchenne News & Articles

Satellos Reports Reduced Muscle Fat Fraction in Biceps MRI and Lower CK Levels in Duchenne Clinical Trial

Satellos Bioscience Inc. has announced a change to the primary efficacy endpoint of its BASECAMP Phase 2 pediatric clinical trial evaluating Forazapadin in Duchenne...

Precision BioSciences Reports Positive Safety Review for PBGENE-DMD: No Serious Adverse Events Through Week Eight

Precision BioSciences has announced a positive safety review of PBGENE-DMD, its investigational gene-editing treatment for Duchenne muscular dystrophy (DMD). An independent Data Safety Monitoring...

Duvyzat (Givinostat) Safety Alert: MHRA Calls for Enhanced Cardiac Monitoring Following Reports of Patient Deaths

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued an important drug safety update concerning Duvyzat (givinostat), a treatment for Duchenne muscular...

PEPR-124 (RT001): An AI-Discovered, Mutation-Agnostic Drug Candidate for Duchenne Muscular Dystrophy

PEPR-124 (also designated as RT001) is an AI-discovered drug candidate developed by Peptris Technologies, a Bengaluru startup based in India, specifically targeting Duchenne Muscular...

RyCarma’s Surlorian (ARM 210) Advances Toward Duchenne Muscular Dystrophy Research

RyCarma Therapeutics is developing Surlorian (ARM 210), an experimental drug that may also be evaluated in Duchenne muscular dystrophy (DMD). In its October 26,...